Professor, Internal Medicine, University of Michigan Medical School
Oncology
Dr. Mark M. Zalupski, MD
|
|
Give Review
Dr. Mark M. Zalupski practices Oncology. He went to Wayne State University School of Medicine. Wayne State University School of Medicine is ranked 63/85 in Research/PrimaryCare. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Mark Zalupski has written publications. He has 101 publications published with PubMed. The lastest paper is: 'Phase II study of CI-958 in colorectal cancer.' Mark M. Zalupski accepts Medicare payments and is listed with Medicare.gov.
Publications
- Implication of suspicious cytology in endoscopic ultrasound-guided fine-needle aspiration for pancreatic Cancer.
- DEPTOR has growth suppression activity against pancreatic Cancer cells.
- A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic Cancer.
- Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic AdenoCarcinoma.
- Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic Cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of ge...
- Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangioCarcinoma.
- A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic Cancer.
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers.
- Randomized clinical trial of a brief and extensive dyadic intervention for advanced Cancer patients and their family caregivers.
- A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal Cancer.
- The Quality-of-Life Effects of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
- Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic Cancer who receive gemcitabine-containing chemotherapy: a poole...
- Prognostic Significance of Carbohydrate Antigen 19-9 in Unresectable Locally Advanced Pancreatic Cancer Treated With Dose-Escalated Intensity Modulated Radiation Thera...
- VEGF remains an interesting target in advanced pancreas Cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fl...
- A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic...
- Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced Sarcoma.
- Phase II Trial of Cetuximab in Patients With Metastatic or Locally Advanced Soft Tissue or Bone Sarcoma.
- Radiation Therapy with Full-Dose Gemcitabine and Oxaliplatin for Unresectable Pancreatic Cancer.
- Systemic therapy for advanced gastrointestinal stromal tumors: Beyond imatinib.
- Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pan...
- Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas Cancer.
- A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic coloRectal c...
- Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic Cancer: a multicenter phase II trial.
- Radiotherapy for locally advanced pancreatic Cancer.
- Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic Cancer.
- Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with Carcinoma of unknown primary site.
- A phase II study of preoperative capecitabine and radiation therapy in patients with rectal Cancer.
- Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic Cancer.
- Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with Sarcoma.
- A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic Carcinoma.
- Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue Sarcoma.
- Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic Cancer.
- A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic Cancer.
- Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study.
- Phase II study of 9-nitro-camptothecin in patients with advanced Chordoma or soft tissue sarcoma.
- Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid Tumors.
- Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxo...
- Adjuvant therapy in pancreatic Cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine.
- Adjuvant therapy of osteoSarcoma--A Phase II trial: Southwest Oncology Group study 9139.
- Treatment of advanced coloRectal carcinoma with oxaliplatin and capecitabine: a phase II trial.
- Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic Cancer.
- Chemoradiotherapy in the treatment of regional pancreatic Carcinoma: a phase II study.
- Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenoCarcinoma of the pancreas.
- Radiation therapy with once-weekly gemcitabine in pancreatic Cancer: current status of clinical trials.
- Gastrointestinal stromal Tumors: chemotherapy and imatinib.
- On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic Cancer.
- Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic Cancer: from the laboratory to the clinic.
- Ifosfamide.
- Deletion 6q in three cases of mixed-type lipoSarcoma in addition to t(12;16)(q13;p11)
- Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue Sarcoma.
- GM-CSF did not allow doxorubicin dose escalation in the MAID regimen: a phase I trial. A Southwest Oncology Group study.
- A pilot trial of continuous infusion 5-fluorouracil with levamisole for adjuvant therapy of colon Cancer.
- Sarcomas: the role of adjuvant chemotherapy and a proposed new staging System.
- Phase I trial of sequential cyclophosphamide, cyclosporin A, and interferon-alpha in patients with Cancer: attempt to induce autologous graft-versus-host reaction to e...
- The heterogeneity of Leukemia occurring after treatment for sarcoma.
- Gemcitabine and UFT plus Oral calcium folinate: phase I study.
- A phase II trial of bryostatin 1 in the treatment of metastatic colorectal Cancer.
- A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary Cancers.
- A phase II study of carboplatin and paclitaxel in esophageal Cancer.
- Chronic Oral administration of CI-994: a phase 1 study.
- A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design.
- Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue Sarcomas: a Southwest Oncology Group study.
- A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction Cancers.
- Retroperitoneal germ cell tumor diagnosed by endoscopic ultrasound-guided fine needle aspiration.
- CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic Cancer treated with gemcitabine based chemotherapy.
- Impact of race, age, and socioeconomic status on participation in pancreatic Cancer clinical trials.
- A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenoCarcinoma of the pancreas.
- A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular Carcinomas.
- A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic Cancer.
- Phase II study of paclitaxel and carboplatin in patients with advanced gastric Cancer.
- Phase II study of liposomal doxorubicin in patients with advanced colorectal Cancer.
- Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic Cancer.
- Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of Sarcoma.
- A phase II study of carboplatin and paclitaxel in adenoCarcinoma of unknown primary.
- A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic coloRectal carcinoma (MCRC).
- External-beam radiotherapy for localized extrahepatic cholangioCarcinoma.
- Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal Cancer.
- A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin.
- Radiotherapy for pancreatic neuroendocrine Tumors.
- Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an Oral prodrug of 5-fluorouracil (5FU).
- Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic Cancer.
- Combined-modality therapy in pancreatic Cancer: current status and future directions.
- Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic Carcinoma.
- Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic Carcinoma: a phase II study.
- Multidrug resistance phenotype in high grade soft tissue Sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy.
- High-grade extraskeletal myxoid chondroSarcoma: a high-grade epithelioid malignancy.
- Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic coloRectal carcinoma: A Southwest Oncolog...
- Phase II study of CI-958 in colorectal Cancer.
- Evaluation of pyrazoloacridine in patients with advanced pancreatic Carcinoma.
- A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric Cancer.
- Cytogenetic aberrations and DNA ploidy in soft tissue Sarcoma. A Southwest Oncology Group Study.
- Flow cytometric Analysis of P-glycoprotein expression and drug efflux in human soft tissue and bone sarcomas.
- Phase II study of pyrazoloacridine in patients with advanced coloRectal carcinoma.
- Primary embryonal rhabdomyoSarcoma of long bone. Case report and review of the literature.
- Ifosfamide and etoposide in the treatment of advanced soft tissue Sarcomas.
- Cytogenetic findings in 19 malignant bone Tumors.
- DNA content parameters of paraffin-embedded soft tissue Sarcomas: optimization of retrieval technique and comparison to fresh tissue.
- Deletion of chromosome 13 in osteoSarcoma secondary to irradiation.
- Development and optimization of tissue preparative methodology for DNA content Analysis of soft tissue neoplasms.
- Systemic adjuvant chemotherapy for soft tissue sarcomas.
Schools
Wayne State University
WsuDetroit Med Center
Wayne St Udetroit Med Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Assurant Health
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Care Network PCP Focus Network
- Group Employees PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- Coventry Health Care
- Emblem Health
- Fidelis Care HMO
- First Health (Coventry Health Care) PPO
- Frontpath Health Coalition
- Golden Rule
- Health Alliance
- Preferred PPO
- Choice Care PPO
- Medicaid
- Medical Mutual of Ohio
- Medicare MCR
- Molina
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- NGS CoreSource
- Paramount
- PHP-Physicians Health Plan
- Priority PPO
- Tricare
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Wayne State University School of Medicine
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1528144490 | |
| NPPES Provider LastName | ZALUPSKI | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 481095912 | |
| NPPES Provider State | MI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1113.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 206.0 | |
| Percent Opioid Claims | 18.51 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1528144490 |
| Last Name Of The Provider | ZALUPSKI |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
|
Dr. Nathalie A. Brophy, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Norah L. Henry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kunal C. Kadakia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Monika L. Burness, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christine M. Veenstra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander T. Pearson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Muneesh Tewari, MD
This Doctor is OpenDoctor Recommended.
|